IL119989A0 - Pharmaceutical compositions for oral treatment of multiple sclerosis - Google Patents

Pharmaceutical compositions for oral treatment of multiple sclerosis

Info

Publication number
IL119989A0
IL119989A0 IL11998997A IL11998997A IL119989A0 IL 119989 A0 IL119989 A0 IL 119989A0 IL 11998997 A IL11998997 A IL 11998997A IL 11998997 A IL11998997 A IL 11998997A IL 119989 A0 IL119989 A0 IL 119989A0
Authority
IL
Israel
Prior art keywords
pharmaceutical compositions
multiple sclerosis
oral treatment
treatment
oral
Prior art date
Application number
IL11998997A
Other languages
English (en)
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Priority to IL11998997A priority Critical patent/IL119989A0/xx
Publication of IL119989A0 publication Critical patent/IL119989A0/xx
Priority to US09/341,369 priority patent/US6214791B1/en
Priority to DE69837324T priority patent/DE69837324T2/de
Priority to PCT/US1998/000375 priority patent/WO1998030227A1/en
Priority to PL334566A priority patent/PL193300B1/pl
Priority to AU58195/98A priority patent/AU737287B2/en
Priority to CZ0243799A priority patent/CZ297983B6/cs
Priority to EA199900621A priority patent/EA003128B1/ru
Priority to SK931-99A priority patent/SK284029B6/sk
Priority to ZA9800214A priority patent/ZA98214B/xx
Priority to JP53110898A priority patent/JP4216342B2/ja
Priority to CA2277365A priority patent/CA2277365C/en
Priority to AT98901745T priority patent/ATE356608T1/de
Priority to KR1019997006278A priority patent/KR20000070058A/ko
Priority to IL13082098A priority patent/IL130820A0/xx
Priority to HK00104810.0A priority patent/HK1025737B/en
Priority to CNB988031221A priority patent/CN100528222C/zh
Priority to EP98901745A priority patent/EP0975351B1/en
Priority to HU0001917A priority patent/HU226612B1/hu
Priority to NZ336690A priority patent/NZ336690A/en
Priority to BRPI9807076A priority patent/BRPI9807076B8/pt
Priority to IL130820A priority patent/IL130820A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/02Peptides of undefined number of amino acids; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Treatments Of Macromolecular Shaped Articles (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • General Preparation And Processing Of Foods (AREA)
IL11998997A 1997-01-10 1997-01-10 Pharmaceutical compositions for oral treatment of multiple sclerosis IL119989A0 (en)

Priority Applications (22)

Application Number Priority Date Filing Date Title
IL11998997A IL119989A0 (en) 1997-01-10 1997-01-10 Pharmaceutical compositions for oral treatment of multiple sclerosis
BRPI9807076A BRPI9807076B8 (pt) 1997-01-10 1998-01-12 "uso de acetato de glatirâmero para a fabricação de medicamento para o tratamento de esclerose múltipla e composição farmacêutica"
JP53110898A JP4216342B2 (ja) 1997-01-10 1998-01-12 コポリマー1の摂取又は吸入を通じての多発性硬化症の治療
AT98901745T ATE356608T1 (de) 1997-01-10 1998-01-12 Behandlung der multiplen sklerose durch einnahme von copolymer-1
PCT/US1998/000375 WO1998030227A1 (en) 1997-01-10 1998-01-12 Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
PL334566A PL193300B1 (pl) 1997-01-10 1998-01-12 Zastosowanie octanu glatirameru oraz kompozycja farmaceutyczna
AU58195/98A AU737287B2 (en) 1997-01-10 1998-01-12 Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
CZ0243799A CZ297983B6 (cs) 1997-01-10 1998-01-12 Entericky potazená farmaceutická kompozice pro perorální podávání pro lécení roztrousené sklerózy
EA199900621A EA003128B1 (ru) 1997-01-10 1998-01-12 Способ лечения рассеянного склероза и фармацевтический состав, содержащий сополимер-1
SK931-99A SK284029B6 (sk) 1997-01-10 1998-01-12 Farmaceutická kompozícia na liečenie roztrúsenej sklerózy
ZA9800214A ZA98214B (en) 1997-01-10 1998-01-12 Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1.
US09/341,369 US6214791B1 (en) 1997-01-10 1998-01-12 Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
CA2277365A CA2277365C (en) 1997-01-10 1998-01-12 Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
DE69837324T DE69837324T2 (de) 1997-01-10 1998-01-12 Behandlung der multiplen sklerose durch einnahme von copolymer-1
KR1019997006278A KR20000070058A (ko) 1997-01-10 1998-01-12 공중합체-1의 섭취 또는 흡입을 통한 다발성 경화증의 치료
IL13082098A IL130820A0 (en) 1997-01-10 1998-01-12 Pharmaceutical composition for oral treatment of multiple sclerosis
HK00104810.0A HK1025737B (en) 1997-01-10 1998-01-12 Treatment of multiple sclerosis through ingestion of copolymer-1
CNB988031221A CN100528222C (zh) 1997-01-10 1998-01-12 共聚物-1在制备治疗多发性硬化症的口服固体药物中的用途
EP98901745A EP0975351B1 (en) 1997-01-10 1998-01-12 Treatment of multiple sclerosis through ingestion of copolymer-1
HU0001917A HU226612B1 (en) 1997-01-10 1998-01-12 Use of glatiramer acetate for production of pharmaceutical composition to the treatment of multiple sclerosis
NZ336690A NZ336690A (en) 1997-01-10 1998-01-12 Copolymer-1 [glatiramer acetate (trade name Copaxone)] consists of L-glutamic acid, L-alanine, L-tryrosine and L-lysine for treating multiple sclerosis
IL130820A IL130820A (en) 1997-01-10 1999-07-06 Pharmaceutical preparations for the oral treatment of multiple sclerosis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL11998997A IL119989A0 (en) 1997-01-10 1997-01-10 Pharmaceutical compositions for oral treatment of multiple sclerosis

Publications (1)

Publication Number Publication Date
IL119989A0 true IL119989A0 (en) 1997-04-15

Family

ID=11069682

Family Applications (2)

Application Number Title Priority Date Filing Date
IL11998997A IL119989A0 (en) 1997-01-10 1997-01-10 Pharmaceutical compositions for oral treatment of multiple sclerosis
IL130820A IL130820A (en) 1997-01-10 1999-07-06 Pharmaceutical preparations for the oral treatment of multiple sclerosis

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL130820A IL130820A (en) 1997-01-10 1999-07-06 Pharmaceutical preparations for the oral treatment of multiple sclerosis

Country Status (18)

Country Link
EP (1) EP0975351B1 (enExample)
JP (1) JP4216342B2 (enExample)
KR (1) KR20000070058A (enExample)
CN (1) CN100528222C (enExample)
AT (1) ATE356608T1 (enExample)
AU (1) AU737287B2 (enExample)
BR (1) BRPI9807076B8 (enExample)
CA (1) CA2277365C (enExample)
CZ (1) CZ297983B6 (enExample)
DE (1) DE69837324T2 (enExample)
EA (1) EA003128B1 (enExample)
HU (1) HU226612B1 (enExample)
IL (2) IL119989A0 (enExample)
NZ (1) NZ336690A (enExample)
PL (1) PL193300B1 (enExample)
SK (1) SK284029B6 (enExample)
WO (1) WO1998030227A1 (enExample)
ZA (1) ZA98214B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2337688C (en) 1998-07-23 2016-04-05 Yeda Research And Development Co., Ltd. Treatment of autoimmune conditions with copolymer 1 and related copolymers
AU766498B2 (en) * 1998-07-23 2003-10-16 President And Fellows Of Harvard College, The Synthetic peptides and methods of use for autoimmune disease therapies
ES2527760T3 (es) 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
US6800287B2 (en) 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
DE60041365D1 (de) * 1999-06-04 2009-02-26 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Verwendung von Riluzol zur Behandlung Multipler Sklerose
WO2000074676A1 (en) * 1999-06-04 2000-12-14 Vereniging Voor Christelijk Wetenschappelikjk Onderwijs Use of riluzole for the treatment of multiple sclerosis
ZA200206457B (en) 2000-02-18 2003-08-13 Yeda Res & Dev Oral, nasal and pulmonary dosage formulations of copolymer 1.
MXPA02008023A (es) * 2000-02-18 2005-06-30 Yeda Res & Dev Formulaciones de copolimero 1 para dosificacion oral, nasal y pulmonar.
US20020077278A1 (en) 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
CA2411536A1 (en) * 2000-06-05 2001-12-13 V. Wee Yong The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
WO2002076503A1 (en) 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
DE60237170D1 (de) 2001-12-04 2010-09-09 Teva Pharma Verfahren zur messung der wirkstärke von glatirameracetat
KR20040105740A (ko) 2002-02-25 2004-12-16 엘란 파마슈티칼스, 인크. 염증 치료제의 투여 방법
SK50642005A3 (sk) * 2003-01-24 2006-02-02 Elan Pharmaceuticals, Inc. Kompozícia na liečenie demyelizačných ochorení a paralýzy podávaním remyelizačných látok
WO2006029411A2 (en) 2004-09-09 2006-03-16 Yeda Research And Development Co. Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
UA103699C2 (ru) 2009-08-20 2013-11-11 Еда Рисёрч Энд Девелопмент Ко., Лтд. Терапия глатирамера ацетатом с низкой частотой
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
EA025780B1 (ru) 2010-10-11 2017-01-30 Тева Фармасьютикал Индастриз Лтд. Цитокиновые биомаркеры в качестве биомаркеров, прогнозирующих клинический ответ на глатирамер ацетат
CA2851510A1 (en) 2011-10-10 2013-04-18 Teva Pharmaceutical Industries Ltd. Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
TW201420111A (zh) 2012-10-10 2014-06-01 Teva Pharma 對格拉默醋酸鹽(glatiramer acetate)之臨床反應具預測性之生物標記
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
CN105884866B (zh) * 2015-01-26 2021-04-20 漳州未名博欣生物医药有限公司 格拉替雷的化学合成方法
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
EP3603764B1 (en) * 2015-04-28 2022-03-30 Hybio Pharmaceutical Co., Ltd. High performance liquid chromatography method for polypeptide mixtures
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
US12370233B2 (en) 2016-08-31 2025-07-29 Mapi Pharma Ltd. Depot systems comprising glatiramer acetate
WO2018178973A1 (en) 2017-03-26 2018-10-04 Mapi Pharma Ltd. Glatiramer depot systems for treating progressive forms of multiple sclerosis
CN110996983A (zh) 2017-06-26 2020-04-10 巴斯德研究所 清除hiv储库并降低病毒载量的治疗

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL113812A (en) * 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
US5719296A (en) * 1995-10-30 1998-02-17 Merck & Co., Inc. Pseudopeptide lactam inhibitors of peptide binding to MHC class II proteins

Also Published As

Publication number Publication date
EP0975351A1 (en) 2000-02-02
CN1249690A (zh) 2000-04-05
ZA98214B (en) 1999-08-11
HUP0001917A2 (hu) 2000-10-28
CN100528222C (zh) 2009-08-19
ATE356608T1 (de) 2007-04-15
EA199900621A1 (ru) 2000-02-28
CA2277365A1 (en) 1998-07-16
JP2001511121A (ja) 2001-08-07
EP0975351B1 (en) 2007-03-14
HUP0001917A3 (en) 2001-12-28
JP4216342B2 (ja) 2009-01-28
DE69837324D1 (de) 2007-04-26
SK93199A3 (en) 2000-11-07
PL334566A1 (en) 2000-03-13
SK284029B6 (sk) 2004-08-03
NZ336690A (en) 2001-05-25
HU226612B1 (en) 2009-04-28
EA003128B1 (ru) 2003-02-27
CA2277365C (en) 2011-04-12
EP0975351A4 (en) 2002-05-15
IL130820A (en) 2007-03-08
AU5819598A (en) 1998-08-03
KR20000070058A (ko) 2000-11-25
BR9807076B1 (pt) 2013-10-29
PL193300B1 (pl) 2007-01-31
DE69837324T2 (de) 2007-11-29
WO1998030227A1 (en) 1998-07-16
AU737287B2 (en) 2001-08-16
BR9807076A (pt) 2000-05-02
HK1025737A1 (en) 2000-11-24
CZ297983B6 (cs) 2007-05-16
BRPI9807076B8 (pt) 2021-05-25
CZ243799A3 (cs) 2000-06-14

Similar Documents

Publication Publication Date Title
IL119989A0 (en) Pharmaceutical compositions for oral treatment of multiple sclerosis
IL113812A (en) Copolymer-1 pharmaceutical compositions containing it and its use
GB0129260D0 (en) Pharmaceutical compositions and their uses
UA39158C2 (uk) Похідні n4-оксикарбоніл-5'-дезокси-5-фторцитидину та фармацевтичний препарат на їх основі
BG103793A (en) COMBINED THERAPY USING BENZOTHIAPINS INHIBITING THE ILEAL BILE ACID TRANSPORT AND HMG Co-A REDUCTASE INHIBITORS
IL108007A (en) USE OF AN INTERFERON-GAMMA (IFN-gamma) INHIBITOR IN THE PREPARATION OF A MEDICAMENT FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE
ZA943744B (en) Therapeutic substituted guanidines
HU9303357D0 (en) Pharmaceutical composition containing well-defined lipide-systhem
WO2000053758A3 (en) Compositions and methods for the treatment of immune related diseases
IL141157A0 (en) Salt form of pantoprazole and pharmaceutical compositions containing the same
AP2000001947A0 (en) Novel crystalline forms of an antiviral benzidazole compound.
YU79202A (sh) Peptid koji modulira trombopoetinski receptor
ATE215817T1 (de) Feste miltefosin enthaltende arzneimittel zur oralen verabreichung bei der behandlung von leishmaniasis
AU4011300A (en) Compositions and methods for the treatment of immune related diseases
MXPA94009086A (es) Guanidinas sustituidas terapeuticas.
WO1999014241A3 (en) Compositions and methods for the treatment of immune related diseases
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
NZ332655A (en) Pharmaceutical compositions containing diclofenac and alkali metal bicarbonates
GB2331926A (en) Pharmaceutical compositions containing ibuprofen and domperidone for the treatment of migraine
IL111805A0 (en) Pharmaceutical compositions comprising dimeticone for the treatment of aphthae
AU6849198A (en) Neurotrypsin
WO2000015797A3 (en) Compositions and methods for the treatment of immune related diseases
GB9015774D0 (en) Novel treatment
GR1002385B (el) Καθαρη μορφη στρεπτογραμινων, παρασκευη αυτης και φαρμακευτικες συνθεσεις που την περιεχουν.
AU7079300A (en) Compositions and methods for the treatment of immune related diseases